NervGen Advances SCI Treatment, Awaits FDA Update Amid Leadership Changes
Event summary
- NervGen reported $22.1 million in cash and investments as of December 31, 2025, up from $17.3 million the prior year.
- The company completed an End-of-Phase 2 meeting with the FDA in 1Q 2026 and anticipates a regulatory update in early 2Q 2026.
- NervGen expects to present biomechanical gait analysis data from the CONNECT SCI study in 2Q 2026.
- Bill Adams retired as CFO in March 2026, and an executive search is underway to replace him.
- The company reported a net loss of $44.1 million for the year ended December 31, 2025, including $24.8 million of non-cash expenses.
The big picture
NervGen's progress in developing NVG-291 represents a significant, albeit early, step toward a pharmacologic treatment for chronic spinal cord injury, a market with substantial unmet need. The company's reliance on FDA approval and the inherent risks of clinical development remain key challenges. The ongoing leadership transition underscores the pressure to deliver on ambitious timelines and maintain investor confidence.
What we're watching
- Regulatory Risk
- The FDA update in early 2Q 2026 will be critical; a negative assessment could significantly impact the Phase 3 trial timeline and investor sentiment.
- Execution Risk
- The transition in CFO leadership introduces execution risk, particularly as the company prepares for a Phase 3 trial and potential commercialization.
- Clinical Data
- The upcoming biomechanical gait analysis data release will be scrutinized to validate the observed functional improvements and differentiate genuine neural recovery from compensatory movement.
Related topics